# Karen A. Gelmon
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/karen-a-gelmon/
## Facts
| Field | Value |
| --- | --- |
| Citations | 56,692 |
| Field | Breast Cancer Treatment Studies |
| h-index | 107 |
| i10-index | 324 |
| Last Known Institution | BC Cancer Agency |
| OpenAlex ID | https://openalex.org/A5067468792 |
| ORCID iD | https://orcid.org/0000-0003-4111-2757 |
| Works | 747 |
## Researcher papers
Showing 12 of 19.
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [The clonal and mutational evolution spectrum of primary triple-negative breast cancers](https://scholariq.org/papers/the-clonal-and-mutational-evolution-spectrum-of-primary-triple-negative-breast/)
- [Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer](https://scholariq.org/papers/adjuvant-olaparib-for-patients-with-i-brca1-i-or-i-brca2-i-mutated-breast-cancer/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies](https://scholariq.org/papers/subtyping-of-breast-cancer-by-immunohistochemistry-to-investigate-a-relationship/)
- [Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution](https://scholariq.org/papers/mutational-evolution-in-a-lobular-breast-tumour-profiled-at-single-nucleotide/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution](https://scholariq.org/papers/dynamics-of-genomic-clones-in-breast-cancer-patient-xenografts-at-single-cell/)
- [Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial](https://scholariq.org/papers/intracranial-efficacy-and-survival-with-tucatinib-plus-trastuzumab-and/)
## Researcher topics
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
## Researcher university
- [BC Cancer Agency](https://scholariq.org/institutions/bc-cancer-agency/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.